PULMONARY HEMORRHAGE AS A CLINICAL MANIFESTATION OF HEMOLYTIC-UREMIC SYNDROME-ASSOCIATED WITH MITOMYCIN-C THERAPY

Mitomycin C (MMC) is an alkylating agent that has been recently associ ated with the hemolytic-uremic syndrome (HUS). Pulmonary impairment in the HUS is rarely reported in the literature, and no reports of pulmo nary hemorrhage, as a clinical feature of the HUS, have been documente d. We describe two women who developed HUS after MMC therapy and prese nted massive pulmonary bleeding. Pulmonary hemorrhage is an uncommon f eature in the HUS, and seems to appear especially in the HUS associate d with MMC therapy. It is extremely resistant to standard treatment, a nd confers a poor prognosis for this disease.